Cognitive Clinical Trials

1. AstraZeneca Pharmaceuticals LP $18,073,990 106 payments
2. Genentech, Inc. $3,688,700 996 payments
3. Boehringer Ingelheim Pharmaceuticals, Inc. $884,819 39 payments
4. Bayer HealthCare Pharmaceuticals Inc. $145,331 47 payments
5. Ipsen Innovation $101,681 64 payments
6. GlaxoSmithKline, LLC. $59,972 12 payments
7. AstraZeneca UK Limited $56,865 7 payments
8. E.R. Squibb & Sons, L.L.C. $45,997 7 payments
9. Novartis Pharmaceuticals Corporation $45,786 3 payments
10. Lexicon Pharmaceuticals, Inc. $38,737 10 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $15,459,974 8 payments
2. Roche Cancer Screening Collection Study $3,688,700 996 payments
3. a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $549,100 19 payments
4. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $428,767 17 payments
5. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $362,243 18 payments
6. Obesity Long term safety in patients with CV risk $350,810 5 payments
7. A Phase IIb Multicenter Randomised DoubleBlind Dose-inding Study to Evaluate the Efficacy Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria $225,061 5 payments
8. Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 $222,388 9 payments
9. A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension $201,206 3 payments
10. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $162,480 2 payments

1. Patient care $38,737 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.